Moleculin Biotech Inc. (0K2H)

Overview

Moleculin Biotech, Inc. represents a pivotal force in the pharmaceutical arena, specifically targeted toward the development of innovative treatments for critical health conditions such as cancers and viruses. Established in 2015 and rooted in the medical hub of Houston, Texas, this clinical stage pharmaceutical company dedicates its scientific endeavors to formulating drug candidates that potentially transform the landscape of cancer treatment and virology. Leveraging a strategic blend of advanced clinical research methodologies and a profound commitment to addressing unmet medical needs, Moleculin Biotech, Inc. undertakes a mission to materialize the promise of next-generation therapeutics that could significantly influence the trajectory of patient care in the realms of oncology and infectious diseases.

Products and Services

• Annamycin

  As the flagbearer of Moleculin Biotech’s innovative pipeline, Annamycin stands out as a lead drug candidate currently under exploration in Phase 1/2 clinical studies. This novel chemotherapeutic agent is meticulously designed to combat relapsed or refractory acute myeloid leukemia (AML) and various cancers that have metastasized to the lungs. Its development underscores the company's dedication to offering new avenues of hope for patients facing limited treatment options.

• WP1066

  In the realm of immune/transcription modulators, WP1066 emerges as Moleculin Biotech’s flagship contender. Currently navigating the Phase I clinical trial, this potential therapeutic powerhouse is aimed at treating an array of malignancies including brain tumors, pediatric brain tumors, pancreatic cancer, and others. WP1066 represents a key component of the company's strategic focus on cutting-edge solutions that modulate immune responses and transcription processes within cancer cells.

• WP1220

  Expanding its portfolio of cancer therapies, Moleculin Biotech is also developing WP1220, an analog of WP1066, specifically for the topical treatment of cutaneous T-cell lymphoma. This marks a significant stride toward addressing skin-associated lymphomas, offering a new dimension of therapeutic intervention that leverages targeted mechanisms to combat tumor cells.

• WP1122

  With a versatile approach in its product development strategy, Moleculin Biotech does not limit its research endeavors to cancer. WP1122 is being explored for its potential in treating glioblastoma multiforme, a notorious form of brain cancer, and has also been pivotally positioned as a candidate for battling COVID-19. This aptly illustrates the company’s agile response to contemporary global health crises by channeling its scientific resources toward combating both longstanding and emerging health threats.